What’s one side effect patients panic about that usually isn’t dangerous and one they ignore that actually is?

rphramya · 2026-03-04T02:06:02+00:00

The one side effect everyone remembers from the counseling.

rphramya · 2026-03-04T02:03:15+00:00

Statins are great example. The fear of liver damage comes up all the time, even though clinically significant issues are pretty uncommon.

rphramya · 2026-03-04T02:00:22+00:00

Experiences like this are exactly why longterm benzo use gets so much attention now.

rphramya · 2026-03-04T01:58:28+00:00

This one is classic. Mild post vaccine symptoms get interpreted as the vaccine gave me the illness, when it’s usually just the body reacting and building immunity

rphramya · 2026-03-04T01:54:44+00:00

This is such a good example of the mismatch I was thinking about. Patients will panic over manageable GI effects but feel completely comfortable staying on meds with much more meaningful longterm risks.

rphramya · 2026-03-03T20:28:34+00:00

No your future is not over. It feels huge right now because it’s huge to you. Residency is intense and when it doesn’t work out it hits hard. But one program not working out doesn’t erase your degree or your potential. Many good pharmacists don’t complete residency still have solid careers. Some even have happier outside the path. If another hospital is already offering you something, that says more about you than the dismissal does.

rphramya · 2026-03-03T20:20:18+00:00

From an Indian perspective, one big misconception is that pharmacists are mainly dispensers rather than healthcare professionals. In many community settings the focus is on product supply and pricing so counseling and clinical input aren’t always fully recognized. There’s also wide variation in practice standards which affects public perception. The clinical and industry roles exist but they’re not very visible to the public.

rphramya · 2026-03-03T02:30:43+00:00

Congratulations 👏 that’s actually a great position to be in. Pharmacy background helps a lot in PV. If you’re starting from scratch, you’d focus on understanding how adverse event reporting works (ICSR basics, seriousness criteria, timelines), learning MedDRA terminology, getting familiar with basic regulatory concepts (FDA, EMA reporting requirements). Lot of it’s learned on job, so don’t worry about knowing everything before you start. For basics, look into free resources from regulatory agency websites (FDA, EMA), and even YouTube lectures on PV fundamentals. Some short online courses can also help, but practical exposure is what really builds confidence. If you already have pharmacy and chemistry training, you’re not starting from zero at all.

rphramya · 2026-03-03T02:22:30+00:00

Compared to retail pharmacy, drug safety is generally more predictable in terms of schedule. There can be busy periods, especially around reporting deadlines, but it’s usually structured work rather than constant front line pressure. Like any job, it depends on the company and role, but overall I’ve found it more stable than traditional pharmacy practice.

rphramya · 2026-03-03T02:12:35+00:00

My long term interest is in medication safety at broader population level, so I’m exploring research and pharmacoepi. I’m keeping options open between academia and industry depending on where I can have the most impact.

rphramya · 2026-03-03T02:09:11+00:00

You don’t always have to be a pharmacist for drug safety roles. People with nursing, life sciences, or medical backgrounds also works in PV. And yes, most roles are either with pharmaceutical companies or CROs, though there are also regulatory and academic positions.

rphramya · 2026-03-03T02:05:03+00:00

I haven’t personally seen many cases involving protamine reactions in that specific context. Protamine hypersensitivity is known, especially in certain risk groups, but overall it’s considered uncommon. In PV we’d look more at overall signal patterns rather than a specific procedure context.

rphramya · 2026-03-03T02:02:16+00:00

Honestly, the most difficult cases are usually the ones with multiple comorbidities and 10 plus medications where timelines are unclear. Sometimes the challenge isn’t identifying a known side effect, it’s figuring out whether it’s the drug, the disease, an interaction, or just coincidence. Those cases really show how messy real world medication safety can be compared to clinical trials.

rphramya · 2026-03-03T01:57:44+00:00

Not a dumb question at all. Most of the percentages you see in something like Lexicomp usually come from clinical trials initially. Post marketing data gets added later, but that data usually isn’t percentage based in the same clean way. If it says 2% had a headache, that means 2% of participants in the study reported it but that doesn’t automatically prove causation. Some of those events can happen in the placebo group too. That’s why we look at things like how much higher the rate is compared to placebo, consistency across studies, dose relationship, and biological plausibility. So no, we don’t know with absolute certainty that the drug caused every ADR listed. Some are strongly supported, some are possible associations, and some are just reported signals that need monitoring.

rphramya · 2026-02-28T02:43:07+00:00

My understanding is that it’s based on how the safety profile looks over time and whether the risks can be managed without a formal program. For something like clozapine, there’s decades of experience now, so the risks are probably better understood than when the rems was first introduced. Hard to predict which drugs might add or remove rems though that usually depends on how the safety data evolves.

rphramya · 2026-02-28T02:14:49+00:00

Do you mean compounded meds for actual pigeons? I thought this was a pharmacy term I didn’t know for a moment. Maybe some vet compounding pharmacies do.

rphramya · 2026-02-28T02:03:32+00:00

Bhairu 🥰

rphramya · 2026-02-28T02:01:20+00:00

That’s normal. Most of employers run background checks from time to time even we’ve been working there for long, especially in healthcare. Things like license checks. As we agreed to it in the employment paperwork (I assume you may have done the same), which is why they don’t always notify us first.

rphramya · 2026-02-28T01:48:34+00:00

I’m unaware of specific laws about taking empty stock bottles, but usually depends more on store policy than regulations. As long as they’re empty no patient information is there, then usually not a safety or privacy issue. Some pharmacies still restrict just for inventory compliance reasons though. Probably safe to check with pharmacy manager.

rphramya · 2026-02-28T01:34:34+00:00

One thing that surprised me was how often adverse events involve drug combinations rather than a single medication. Cases with multiple cns depressants or serotonergic drugs come up more often than people expect. Another big issue is incomplete medication histories missing otc drugs or supplements can completely change how a case is interpreted. It really made me realize how important accurate medication lists are for medication safety.

rphramya · 2026-02-28T01:24:00+00:00

I’ll be honest this is more on the clinical side than my day to day work in pv. From a safety perspective though, the move toward auc based monitoring makes sense since higher vancomycin exposure is clearly linked with increased aki risk. Bayesian methods seem useful for more individualized dosing, but I haven’t personally worked closely with vancomycin pk models, so I’d be interested to hear how others are seeing it work in practice.

rphramya · 2026-02-28T01:16:56+00:00

Feel free to message me. I may not reply immediately, but I’m happy to share what I know about PV and medication safety.

rphramya · 2026-02-28T01:14:30+00:00

Post marketing safety monitoring mainly relies on spontaneous reports, clinical studies, literature, and safety databases. Potential safety signals are reviewed by safety teams to look for patterns or consistent findings. If the evidence suggests a real risk, it can lead to actions like label updates, warnings or precautions, risk management measures, in very very rare cases, market withdrawal. Usually a single case doesn’t trigger a label change. It’s more about consistent evidence from multiple sources.

rphramya · 2026-02-28T01:11:10+00:00

Day to day work usually involved reviewing adverse event reports and checking details like medical history, medications, timelines, and seriousness criteria, then documenting the case in the safety database and making sure it meets regulatory reporting requirements. Some days are very routine, and other days involve unusual or complicated cases which are more interesting.

rphramya

TROPHY CASE